CN112689517A - 提高抗癌药剂效能的方法 - Google Patents

提高抗癌药剂效能的方法 Download PDF

Info

Publication number
CN112689517A
CN112689517A CN201980050535.0A CN201980050535A CN112689517A CN 112689517 A CN112689517 A CN 112689517A CN 201980050535 A CN201980050535 A CN 201980050535A CN 112689517 A CN112689517 A CN 112689517A
Authority
CN
China
Prior art keywords
ala
leu
gly
val
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980050535.0A
Other languages
English (en)
Chinese (zh)
Inventor
让·德冈兹伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Da Volterra SAS
Original Assignee
Da Volterra SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Da Volterra SAS filed Critical Da Volterra SAS
Publication of CN112689517A publication Critical patent/CN112689517A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006—Beta-lactamase (3.5.2.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201980050535.0A 2018-08-05 2019-08-05 提高抗癌药剂效能的方法 Pending CN112689517A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18187408.2 2018-08-05
EP18187408 2018-08-05
PCT/EP2019/071024 WO2020030591A1 (en) 2018-08-05 2019-08-05 Method for improving anticancer agent efficacy

Publications (1)

Publication Number Publication Date
CN112689517A true CN112689517A (zh) 2021-04-20

Family

ID=63165228

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980050535.0A Pending CN112689517A (zh) 2018-08-05 2019-08-05 提高抗癌药剂效能的方法

Country Status (11)

Country Link
US (1) US20210299170A1 (https=)
EP (1) EP3829637A1 (https=)
JP (1) JP2021534091A (https=)
KR (1) KR20210040997A (https=)
CN (1) CN112689517A (https=)
AU (1) AU2019317986A1 (https=)
BR (1) BR112021002106A2 (https=)
CA (1) CA3106429A1 (https=)
IL (1) IL280608A (https=)
MX (1) MX2021001394A (https=)
WO (1) WO2020030591A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4291238A4 (en) * 2021-02-10 2024-10-09 Great Novel Therapeutics Biotech & Medicals Corporation PHARMACEUTICAL COMBINATION AND METHOD FOR OVERCOMING IMMUNE SUPPRESSION OR STIMULATING AN IMMUNE RESPONSE AGAINST CANCER

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061019A1 (en) * 2001-02-01 2002-08-08 Seng-Ha Hoang Manufacturing method of pine charcoal and novel use thereof as an anticancer agent
CN1657100A (zh) * 2004-02-19 2005-08-24 中国人民解放军军事医学科学院毒物药物研究所 选择性靶向胃癌和淋巴系统的纳米级制剂及其制备方法
CN101128187A (zh) * 2005-02-09 2008-02-20 达沃尔泰拉公司 活性剂的结肠递送
CN102869351A (zh) * 2010-02-23 2013-01-09 达·沃尔泰拉公司 用于吸附剂在肠内的经口递送的制剂
WO2017003908A1 (en) * 2015-06-30 2017-01-05 The Trustees Of Columbia University In The City Of New York Talc-bound compositions and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249100B2 (en) 2005-05-18 2012-01-19 Assistance Publique - Hospitaux De Paris Colonic delivery of adsorbents
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
FI119190B (fi) 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
EP2897594B1 (en) 2012-09-21 2020-04-08 Ferring B.V. Pharmaceutical composition
EP2876167A1 (en) * 2013-11-21 2015-05-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
US9290754B2 (en) 2014-04-17 2016-03-22 Synthetic Biologics Inc. Beta-lactamases with improved properties for therapy
FR3027307B1 (fr) 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
JP7113619B2 (ja) * 2014-12-09 2022-08-05 イプセン バイオファーム リミティド リポソーマルイリノテカンによる乳がんの治療
BR112017025813A2 (pt) * 2015-06-01 2018-08-14 Univ Chicago método, kit ou composição, micróbio comensal benéfico, método para tratar ou prevenir o câncer e formulação bacteriana

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061019A1 (en) * 2001-02-01 2002-08-08 Seng-Ha Hoang Manufacturing method of pine charcoal and novel use thereof as an anticancer agent
CN1657100A (zh) * 2004-02-19 2005-08-24 中国人民解放军军事医学科学院毒物药物研究所 选择性靶向胃癌和淋巴系统的纳米级制剂及其制备方法
CN101128187A (zh) * 2005-02-09 2008-02-20 达沃尔泰拉公司 活性剂的结肠递送
CN102869351A (zh) * 2010-02-23 2013-01-09 达·沃尔泰拉公司 用于吸附剂在肠内的经口递送的制剂
WO2017003908A1 (en) * 2015-06-30 2017-01-05 The Trustees Of Columbia University In The City Of New York Talc-bound compositions and uses thereof

Also Published As

Publication number Publication date
AU2019317986A1 (en) 2021-02-11
CA3106429A1 (en) 2020-02-13
BR112021002106A2 (pt) 2021-06-01
WO2020030591A1 (en) 2020-02-13
KR20210040997A (ko) 2021-04-14
MX2021001394A (es) 2021-04-12
US20210299170A1 (en) 2021-09-30
JP2021534091A (ja) 2021-12-09
EP3829637A1 (en) 2021-06-09
IL280608A (en) 2021-03-25

Similar Documents

Publication Publication Date Title
CA3085634C (en) A conjugate of a tubulysin analog with branched linkers
CA3236852A1 (en) Bcma monoclonal antibody and the antibody-drug conjugate
CN104530413B (zh) 一种多官能化h型聚乙二醇衍生物修饰的生物相关物质
CN106146670B (zh) 一种新的重组双功能融合蛋白及其制备和应用
KR20200125637A (ko) 마이크로바이옴 관련 면역요법
CN112601554A (zh) 肿瘤微环境活化的药物-结合剂缀合物和与其相关的用途
CA3115741A1 (en) Conjugation linkers containing 2,3-diaminosuccinyl group
CA3072032A1 (en) Compositions and methods for maintaining and restoring a healthy gut barrier
KR20140029372A (ko) 항생제 그리고 분산제 또는 항-부착제를 포함하는 조성물
WO2025242184A1 (en) Compounds, conjugates, and pharmaceutical compositions
CN112689517A (zh) 提高抗癌药剂效能的方法
Sharma et al. Bacterial immunotherapy: is it a weapon in our arsenal in the fight against cancer?
CA3167386A1 (en) A bacterial composition for the treatment of cancer
JP2022522843A (ja) エピジェネティック調節と免疫チェックポイント遮断の組み合わせのための薬物送達
EP3762376B1 (en) Diphenyl substituted thiophene-2-amide derivatives and pharmaceutical compositions thereof useful as antimicrobial
CN112689506A (zh) 用于治疗移植物抗宿主疾病的组合物
CN115697324B (zh) 栗木鞣花素或其类似物用于抗癌功效和增加对免疫检查点抑制剂的应答的用途
WO2022101269A1 (en) Formulations and dosage regimen for oral delivery of adsorbents in the gut
WO2022101267A2 (en) Compositions for delivery of an adsorbent
CN101896193B (zh) 减轻抗癌药副作用的药剂
WO2022084550A1 (en) Compositions for use in the treatment or prevention of dysbiosis
JP2021533150A5 (https=)
US20250064972A1 (en) Method for treating cancer
WO2024196783A1 (en) Bioengineered colon-specific immune niche for the treatment of ulcerative colitis
Axelsen Antibacterial Agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210420